enGene Sinks Below Cash Floor; Opportunity or Value Trap?

What happened

EnGene's stock has fallen below its $4.66 cash floor after weak Phase 2 data showed only a 25% 12-month complete response rate, underperforming competitors like Adstiladrin and Anktiva. The Seeking Alpha article argues the selloff is overdone, citing a strong safety profile, RMAT and Fast Track designations, and cash runway into 2H28. However, the prior DeepValue report rated ENGN a WAIT at $11.11, noting that valuation already priced in approval without clear differentiation. The decline to sub-cash levels reduces downside risk but does not resolve the fundamental question of whether detalimogene can compete effectively. Investors must weigh the tangible cash floor against the binary risk of pivotal LEGEND data due in late 2026.

Implication

With shares trading below net cash, downside is largely limited to cash burn, yet upside hinges entirely on positive pivotal data and commercial adoption. The 25% 12-month CR is disappointing versus competitors' 50%+ rates, making approval and uptake uncertain. However, RMAT designation and CDRP participation suggest a streamlined regulatory path, and cash runway into 2H28 reduces near-term dilution risk. Conservative investors should wait for LEGEND data, while aggressive speculators may see favorable risk/reward at cash levels. Ultimately, this is a binary bet on a single asset in a competitive landscape; position sizing must reflect the high probability of failure.

Thesis delta

The previous WAIT rating was based on the stock at $11.11 with a base case of $12. The selloff below cash floor ($4.66) creates a more attractive entry but does not change the fundamental thesis; it shifts risk/reward, making a small speculative position more justifiable while awaiting pivotal data.